The FDA has rejected Tricida’s filing for approval of a treatment for metabolic acidosis in patients with chronic kidney disease. Tricida said it may need to run another clinical trial to fix the deficiencies that led the FDA to issue the complete response letter.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,